Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer

NCT05344209 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

138

Enrollment

OTHER

Sponsor class

Conditions

Oncology
NSCLC Stage IV
NSCLC, Stage III

Interventions

BIOLOGICAL: UV1
DRUG: Sagramostim
DRUG: Anti-PD-1/PD-L1 treatment

Sponsor

Vestre Viken Hospital Trust

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]